Latest Eli Lilly and Company Stories
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Los Angeles, CA (PRWEB) June 18, 2013 The diabetes drug safety center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. The FDA met with drug makers last week to decide additional safety studies of the drug after reports linking it to pancreatic cancer*. The goal of DrugRisk is to improve the safety of...
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia-- low blood sugar-- compared with the commercially available insulin glargine, a new meta-analysis study finds. Results of the combined analysis, of five completed clinical trials, will be presented Tuesday at The Endocrine Society's 95th Annual Meeting in San Francisco. The studies included nearly 3,400 adults with type 2 diabetes who had a daily injection of either insulin...
INDIANAPOLIS, June 18, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable September 10, 2013 to shareholders of record at the close of business on August 15, 2013. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide...
The firm is actively filing Actos lawsuits on behalf of those who suffered from the serious alleged side effects of the drug. (PRWEB) June 17, 2013 On June 10 a woman filed a lawsuit in New Jersey federal court against Takeda, maker of the popular diabetes drug Actos, claiming that Actos caused her father to eventually die of bladder cancer. The Rottenstein Law Group LLP maintains an Actos Lawsuit Information Center at http://www.rotlaw.com/takeda-actos, designed to provide background...
Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO(®) (pitavastatin) 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin...
Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say may be fueled by misguided concern by patients and their caregivers. Calling the rate of missed doses "unacceptably high," the researchers add that hospitalized patients are at a significantly greater risk of developing venous thromboembolism, or VTE, and that...
TORONTO, June 17, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a US$7 million milestone payment. Lilly and Transition have amended their agreement to address future development of...
New video reveals diabetes struggles, chase for Olympic gold and the spirit of a champion INDIANAPOLIS, June 17, 2013 /PRNewswire/ -- News Highlights #T1DiabetesChamp Kris Freeman @TeamFreeBirdXC visits 10 #diabetes #camps; has helped inspire more than 6,500 campers through Lilly program Lilly is one of the largest supporters of #diabetes #camps in the US Lilly Diabetes releases new Kris Freeman video; he reveals diabetes struggles, chase for Olympic gold and the spirit of a...
Alert: Diabetes Drug Actos Has Allegedly Been Linked to Serious Health Problems, Including Bladder Cancer DALLAS (PRWEB) June 14, 2013 National plaintiffs’ law firm Baron and Budd is now handling lawsuits regarding the alleged adverse side effects of the diabetes drug Actos. Actos, also known as pioglitazone, has been prescribed since 1999 to help treat type 2 diabetes. The drug was marketed to help people control blood sugar levels with a minimum of side effects, making it a...
Researchers at Washington University School of Medicine in St. Louis have identified a way to trigger reproduction in the laboratory of clusters of human cells that make insulin, potentially removing a significant obstacle to transplanting the cells as a treatment for patients with type 1 diabetes. Efforts to make this treatment possible have been limited by a dearth of insulin-producing beta cells that can be removed from donors after death, and by the stubborn refusal of human beta cells...
Latest Eli Lilly and Company Reference Libraries
The pancreas is a digestive and an endocrine organ with both endocrine and exocrine functions. It is about six inches long located in the upper portion of the abdominal cavity. The head of the pancreas lies within the indentation of the duodenum and is connected to it by the pancreatic duct. The uncinate process extends from the head and the neck connects to the body of the pancreas, which lies directly behind the stomach. The tail of the pancreas extends to the left side of the body and is...
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
